…
Agronomics Limited is a private equity and venture capital firm specializing in emerging growth, seed/startup, early venture, series B and growth capital investments. The firm invests in quoted and unquoted companies. It prefers to invest in the alternative proteins company with a focus on cellular agriculture, cultivated meat, technologies, nascent industry of modern foods and materials, biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. It also seeks to invest in clean food and biomanufacturing. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It makes minority investments in portfolio companies. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. The firm prefers to invest from its balance sheet capital. Agronomics Limited was founded on May 3, 2011 and is based in Ramsey, Isle of Man.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Agronomics Ltd is a London-listed investment company that backs early-stage and scaling businesses in cellular agriculture, cultivated proteins and precision fermentation. Long-term growth may be driven by rising demand for sustainable proteins, technological progress that lowers production costs and broader commercialization. The company provides public-market exposure to a diversified portfolio in a sustainability-focused subsector.
Principal risks include technology and execution failure common to early-stage food-tech, regulatory and consumer acceptance uncertainty, funding needs for portfolio companies and significant share volatility from illiquid holdings.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -32.75M | -10.99M | 22.37M | 8.36M | 1.02M |
| Net income | -32.75M | -10.99M | 22.37M | 5.96M | -7.70M |
| Selling general administrative | 0.55M | 0.15M | 3.49M | 5.68M | 8.08M |
| Selling and marketing expenses | - | 0.18M | 0.15M | 0.14M | - |
| Gross profit | - | -8.34M | 29.70M | - | - |
| Ebit | - | - | -10.28M | 11.10M | 9.74M |
| Ebitda | -26.47M | - | -34.84M | -11.35M | -20.36M |
| Depreciation and amortization | - | 10.02M | -24.57M | -22.44M | -30.10M |
| Operating income | -26.47M | -12.16M | 24.57M | 11.10M | 9.74M |
| Other operating expenses | 14.56M | 3.82M | 5.13M | 4.92M | 9.69M |
| Interest expense | - | - | - | 0.34M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 1.47M | 1.17M | 1.17M | 0.34M | 0.15M |
| Net interest income | 1.47M | 1.17M | 1.17M | 0.34M | 0.15M |
| Income tax expense | - | - | 24.56M | 2.40M | 8.72M |
| Total revenue | -11.92M | -8.34M | 29.70M | 0.00M | 0.00M |
| Total operating expenses | 14.56M | 3.82M | 5.13M | 4.92M | 9.69M |
| Total other income expense net | -6.28M | 1.18M | -2.20M | -2.74M | -8.72M |
| Net income from continuing ops | -32.75M | -10.99M | 22.37M | 8.36M | 1.02M |
| Net income applicable to common shares | - | - | - | 8.36M | 1.02M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 124.67M | 157.44M | 170.20M | 146.40M | 101.65M |
| Other current assets | -124.67M | 8.71M | 141.77M | 0.10M | 0.45M |
| Total liab | 0.15M | 0.17M | 1.95M | 2.49M | 1.62M |
| Total stockholder equity | 124.52M | 157.27M | 168.26M | 143.91M | 100.03M |
| Other current liab | 0.15M | 0.06M | 1.74M | 2.34M | 1.52M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -11.65M | 21.10M | 32.09M | 9.71M | 1.36M |
| Other assets | 124.67M | 157.44M | -132.66M | - | - |
| Cash | 3.61M | 3.13M | 18.09M | 31.46M | 62.44M |
| Total current liabilities | 0.15M | 0.17M | 1.95M | 2.49M | 1.62M |
| Net debt | -3.61M | -3.13M | -18.09M | -31.46M | -62.44M |
| Other stockholder equity | 136.17M | 136.17M | 134.48M | 134.20M | 98.67M |
| Total current assets | 19.07M | 20.95M | 170.20M | 146.40M | 101.65M |
| Net tangible assets | - | - | - | 143.91M | 100.03M |
| Short term investments | 121.01M | 9.11M | 10.00M | 114.84M | 38.77M |
| Net receivables | 0.05M | 8.71M | 0.34M | 0.10M | 0.45M |
| Inventory | - | - | -141.77M | - | - |
| Accounts payable | 0.09M | 0.11M | 0.20M | 0.15M | 0.10M |
| Accumulated other comprehensive income | - | - | 1.69M | - | - |
| Non currrent assets other | - | 9.11M | 141.77M | - | - |
| Non current assets total | 105.60M | 136.49M | 132.66M | 0.00M | 0.00M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | 9.11M | 0.89M | 10.02M | -20.02M | -20.02M |
| Change to liabilities | - | - | - | 0.87M | 1.69M |
| Total cashflows from investing activities | 1.59M | 0.89M | 10.02M | -20.02M | -20.02M |
| Net borrowings | - | - | - | - | 1.90M |
| Total cash from financing activities | 0.00M | 0.00M | 1.01M | 31.25M | 71.82M |
| Net income | -32.75M | -10.99M | 22.37M | 8.36M | 1.02M |
| Change in cash | -8.63M | -14.97M | -13.36M | -30.98M | 59.65M |
| Begin period cash flow | 12.24M | 18.09M | 31.46M | 62.44M | 2.79M |
| End period cash flow | 3.61M | 3.13M | 18.09M | 31.46M | 62.44M |
| Total cash from operating activities | -1.12M | -15.86M | -24.40M | -42.21M | -12.17M |
| Issuance of capital stock | 0.00M | 0.00M | 0.28M | 32.06M | 73.37M |
| Other cashflows from investing activities | 9.11M | 0.89M | 10.02M | - | - |
| Change to account receivables | 0.00M | 0.28M | -0.23M | 0.32M | -0.43M |
| Other cashflows from financing activities | - | - | 0.73M | -0.80M | -1.55M |
| Change to netincome | - | - | - | -51.76M | -14.45M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.01M | -1.50M | -0.77M | 1.19M | 1.26M |
| Stock based compensation | - | - | 1.69M | - | - |
| Other non cash items | 31.65M | -3.37M | -46.00M | -51.76M | -14.45M |
| Free cash flow | -1.12M | -15.86M | -23.67M | -42.21M | -12.17M |
Sector: Financial Services Industry: Asset Management
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ANIC Agronomics Ltd |
- -% |
4.40 | - | 6.69 | 3.96 | 0.50 | 166.84 | 5.59 |
| MNTN Schiehallion Fund Ltd |
-0.01 0.46% |
2.18 | 0.05 | - | 4.35 | 1.25 | 5.65 | - |
| BHMU BH Macro Limited |
- -% |
4.29 | 0.09 | - | 39.01 | 0.71 | 6.47 | - |
| TFG Tetragon Financial Group Ltd |
0.15 1.00% |
15.10 | 0.02 | 7.04 | 1.16 | 0.31 | 2.06 | 6.56 |
| BPCR BioPharma Credit PLC |
0.00 0.41% |
0.98 | 0.09 | - | 6.73 | 0.91 | 7.95 | - |
Agronomics Limited is a private equity and venture capital firm specializing in emerging growth, seed/startup, early venture, series B and growth capital investments. The firm invests in quoted and unquoted companies. It prefers to invest in the alternative proteins company with a focus on cellular agriculture, cultivated meat, technologies, nascent industry of modern foods and materials, biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. It also seeks to invest in clean food and biomanufacturing. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It makes minority investments in portfolio companies. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. The firm prefers to invest from its balance sheet capital. Agronomics Limited was founded on May 3, 2011 and is based in Ramsey, Isle of Man.
| Name | Title | Year Born |
|---|---|---|
| Mr. Denham Hervey Newall Eke | Fin. Director & Exec. Director | 1952 |
| Mr. James Mellon M.A. | Exec. Director | 1957 |
| Mr. Anthony Chow CFA | Co-Founder | NA |
| Mr. James Mellon M.A. | Co-Founder & Executive Chairperson | 1957 |
| Mr. Denham Hervey Newall Eke | Finance Director & Executive Director | 1951 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.